Construction of the plant will commence in 2025 with first production expected to be in 2027
The Notes shall not be offered or sold in India
ALS patients experience neuroinflammation and rapid neurodegeneration
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Subscribe To Our Newsletter & Stay Updated
